Sunday - January 21, 2018
Research News Roundup: Promising Kyprolis Results, Another FDA Approval, Launch of a New Collaboration
July 13, 2017
NORTH HOLLYWOOD, Calif., July 13 -- The International Myeloma Foundation issued the following news:

This was a busy week in the world of cancer research!

Amgen announced promising follow-up results from the ASPIRE trial in which KRd (Kyprolis(R), Revlimid(R) and dexamethasone) has produced a median overall survival of 48.3 months versus Rd's 40.4 months for patients in the first relapse setting. This is clearly an important survival advantage. Previously, in the ENDEAVO . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

What's your
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products